Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kelly Marek"'
Autor:
Ruth Biehl, Anna Yu, Mary A. Kelly, Zartash Gul, Joan C. Pehta, Robertson D. Davenport, Jose A. Cancelas, Shawnagay Nestheide, Glen Michael Fitzpatrick, Catherine Broome, Zbigniew M. Szczepiorkowski, Bridget Kinne, Neeta Rugg, Ben Antebi, Hagop M. Kantarjian, Maro Ohanian, Vinod Pullarkat, Tor Hervig, Kelly Marek, Fleur M. Aung
Publikováno v:
American journal of hematologyREFERENCES. 97(3)
Thrombosomes are trehalose-stabilized, freeze-dried group O platelets with a 3-year shelf life. They can be stockpiled, rapidly reconstituted, and infused regardless of the recipient's blood type. Thrombosomes thus represent a potential alternative p
Autor:
Nicholas J. Short, Ghayas C. Issa, Guillermo Garcia-Manero, Uday R. Popat, Naval Daver, Rashmi Malla, Koichi Takahashi, Kapil N. Bhalla, Gautam Borthakur, Farhad Ravandi, Nitin Jain, Hagop M. Kantarjian, Elias Jabbour, Jorge E. Cortes, Tapan M. Kadia, Guillermo Montalban Bravo, Marina Konopleva, Maro Ohanian, Naveen Pemmaraju, Rashmi Kanagal-Shamanna, Kelly Marek, Michael Andreeff, Mark Brandt, Alessandra Ferrajoli, Courtney D. DiNardo, Koji Sasaki
Publikováno v:
Blood. 136:17-19
Background Treatment of older patients with newly diagnosed AML has been limited by modest response rates with low-intensity therapy and higher levels of toxicity with intensive therapy. We previously reported on a low-intensity backbone of cladribin
Autor:
Elias Jabbour, Koichi Takahashi, Kapil N. Bhalla, Guillermo Garcia-Manero, Rashmi Malla, Naval Daver, Caitlin R. Rausch, Naveen Pemmaraju, Nitin Jain, Farhad Ravandi, Uday R. Popat, Marina Konopleva, Patrick K. Reville, Michael Andreeff, Hagop M. Kantarjian, Maro Ohanian, Guillermo Montalban-Bravo, Gautam Borthakur, Kelly Marek, Nicholas J. Short, Koji Sasaki, Alessandra Ferrajoli, Ghayas C. Issa, Tapan M. Kadia, Mark Brandt, Courtney D. DiNardo
Publikováno v:
Blood. 138:367-367
Background The combination of venetoclax and 5-azacytidine (5-AZA) for older and unfit patients with newly diagnosed AML has led to significant improvements in remission rates and survival compared to 5-AZA alone. We previously reported encouraging r
Autor:
Tawni Goodman, Prithviraj Bose, Kelly Marek, Sean M. Devlin, Srdan Verstovsek, Nicole Ard, Eytan M. Stein, Michael J. Mauro, Naveen Pemmaraju, Tapan M. Kadia, Kelsey Alvarez, Raajit K. Rampal
Publikováno v:
Blood. 132:354-354
Background: Among the most frequent and challenging hematologic manifestations of myelofibrosis (MF) are anemia and thrombocytopenia, the presence of which portends an adverse outcome. Few effective modalities to address these cytopenias exist, parti